CHEM-X-INFINITY partnered with I-Stem Institute to identify new treatments for monogenic diseases. Chem-X-Infinity will supply compound libraries, library focusing and early hit-optimization.
CHEM-X-INFINITY is pleased to announce a new library focused on kinases, DNA processing enzymes and GPCRs. The original azaindole scaffold could be useful for the identification of new potent series....
There are still a lot of orphan receptors, particularly among GPCRs. The only way to have a chance to identify an active molecule is to assay a great diversity of structures. For those screenings we design diverse libraries with several original substructures. This is our Explora series.
• development of a new CNS predictive QSAR model
• model based on 975 drugs, from which around 90 % of them were correctly classified
• systematic CNS prediction on Chem-X-Infinity’s libraries
• 2,000+ compounds of high diversity available
• cherry-picking and custom format available
• highly diverse exploration of indole-like structures
• privileged structure for aminergic and peptidergic GPCRs
• related to well-established drug series and natural products with complex and interesting pharmacology
• sophisticated production process increasing structural diversity
• library based on 56 intermediates
• highly diverse exploration of aminopyridines, aminopyrimidines and purine-like structures
• privileged structure for kinase and phosphodiesterase inhibitors, GPCR agonists and antagonists
• high diversity of potential targets
• scaffolds related to interesting leads for the exploration of the "kinome" and to natural derivatives with complex pharmacology
• sophisticated production process increasing structural diversity
• library based on 48 intermediates
• highly original scaffolds
• high diversity of potential targets
• limited number of structures around each scaffold to quickly assess the relevance of each series
• library based on 60 intermediates
